Literature DB >> 35196196

miR-4461 inhibits the progression of Gallbladder carcinoma via regulating EGFR/AKT signaling.

Xingzhou Yan1, Pinghua Yang1, Hu Liu1, Yongyang Zhao1, Zhixiong Wu2, Baohua Zhang1.   

Abstract

Increasing evidence has demonstrated that microRNAs (miRNAs) participated in the tumorigenesis, progression and recurrence of various malignancies including Gallbladder carcinoma (GBC). miR-4461 was reported to work as a tumor suppressor gene in renal cell carcinoma. However, the role of miR-4461 in GBC remains unknown. Herein, we show that miR-4461 is downregulated in gallbladder cancer stem cells (CSCs). Forced miR-4461 expression attenuates the self-renewal, tumorigenicity of gallbladder CSCs, and inhibits proliferation and metastasis of GBC cells. Conversely, miR-4461 knockdown promotes the self-renewal of gallbladder CSCs, and facilities proliferation and metastasis of GBC cells. Mechanistically, miR-4461 inhibits GBC progression via downregulating EGFR/AKT pathway. Special EGFR siRNA or AKT overexpression virus abolishes the discrepancy of self-renewal, tumorigenesis, growth, and metastasis between miR-4461 overexpression GBC cells and their control cells. In conclusion, miR-4461 suppresses GBC cells self-renewal, tumorigenicity, proliferation, and metastasis by inactivating EGFR/AKT signaling, and may therefore prove to be a potential therapeutic target for GBC patients.

Entities:  

Keywords:  AKT; EGFR; Gallbladder carcinoma; cancer stem cell; miR-4461

Mesh:

Substances:

Year:  2022        PMID: 35196196      PMCID: PMC9103642          DOI: 10.1080/15384101.2022.2042775

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  31 in total

Review 1.  EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells.

Authors:  Sarmistha Talukdar; Luni Emdad; Swadesh K Das; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2020-06-15       Impact factor: 6.242

2.  CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity.

Authors:  Cheng-Jian Shi; Jun Gao; Min Wang; Xin Wang; Rui Tian; Feng Zhu; Ming Shen; Ren-Yi Qin
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

3.  MiR-4461 Inhibits Tumorigenesis of Renal Cell Carcinoma by Targeting PPP1R3C.

Authors:  Yuanyuan Zhao; Gang Ye; You Wang; Dan Luo
Journal:  Cancer Biother Radiopharm       Date:  2020-09-11       Impact factor: 3.632

4.  Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer's disease.

Authors:  Hannah Walgrave; Sriram Balusu; Sarah Snoeck; Elke Vanden Eynden; Katleen Craessaerts; Nicky Thrupp; Leen Wolfs; Katrien Horré; Yannick Fourne; Alicja Ronisz; Edina Silajdžić; Amber Penning; Giorgia Tosoni; Zsuzsanna Callaerts-Vegh; Rudi D'Hooge; Dietmar Rudolf Thal; Henrik Zetterberg; Sandrine Thuret; Mark Fiers; Carlo Sala Frigerio; Bart De Strooper; Evgenia Salta
Journal:  Cell Stem Cell       Date:  2021-05-24       Impact factor: 24.633

5.  Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.

Authors:  Sherif Abdelaziz Ibrahim; Ramy Gadalla; Eslam A El-Ghonaimy; Omnia Samir; Hossam Taha Mohamed; Hebatallah Hassan; Burkhard Greve; Mohamed El-Shinawi; Mona Mostafa Mohamed; Martin Götte
Journal:  Mol Cancer       Date:  2017-03-07       Impact factor: 27.401

6.  Identification of exosomal miRNAs as diagnostic biomarkers for cholangiocarcinoma and gallbladder carcinoma.

Authors:  Xin-Ying Xue; Yu-Xia Liu; Chen Wang; Xin-Jin Gu; Zhi-Qiang Xue; Xue-Lei Zang; Xi-Dong Ma; Hui Deng; Rong Liu; Lei Pan; San-Hong Liu
Journal:  Signal Transduct Target Ther       Date:  2020-06-12

7.  Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis.

Authors:  Hao Liu; Ying Song; Huishi Qiu; Yanzhen Liu; Kai Luo; Yanmei Yi; Guanmin Jiang; Minying Lu; Zhijie Zhang; Jiang Yin; Shanshan Zeng; Xiangzhou Chen; Min Deng; Xiaoting Jia; Yixue Gu; Danyang Chen; Guopei Zheng; Zhimin He
Journal:  Cell Death Differ       Date:  2019-07-11       Impact factor: 15.828

8.  miR-186 Inhibits Liver Cancer Stem Cells Expansion via Targeting PTPN11.

Authors:  Haochen Yao; Ziting Yang; Yan Lou; Juanjuan Huang; Pinghua Yang; Weiqi Jiang; Shuai Chen
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

9.  EGFR activation limits the response of liver cancer to lenvatinib.

Authors:  Haojie Jin; Yaoping Shi; Yuanyuan Lv; Shengxian Yuan; Christel F A Ramirez; Cor Lieftink; Liqin Wang; Siying Wang; Cun Wang; Matheus Henrique Dias; Fleur Jochems; Yuan Yang; Astrid Bosma; E Marielle Hijmans; Marnix H P de Groot; Serena Vegna; Dan Cui; Yangyang Zhou; Jing Ling; Hui Wang; Yuchen Guo; Xingling Zheng; Nikita Isima; Haiqiu Wu; Chong Sun; Roderick L Beijersbergen; Leila Akkari; Weiping Zhou; Bo Zhai; Wenxin Qin; René Bernards
Journal:  Nature       Date:  2021-07-21       Impact factor: 49.962

10.  Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation.

Authors:  Sang-Hyun Lee; Jin-Man Kim; Dong Gwang Lee; Jangwook Lee; Jong-Gil Park; Tae-Su Han; Hyun-Soo Cho; Young-Lai Cho; Kwang-Hee Bae; Young-Jun Park; Seon-Jin Lee; Moo-Seung Lee; Yong-Min Huh; Deog Yeon Jo; Hwan-Jung Yun; Heung Jin Jeon; Nayoung Kim; Mina Joo; Jang-Seong Kim; Hyo Jin Lee; Jeong-Ki Min
Journal:  Cell Death Differ       Date:  2020-09-28       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.